



Texas Healthcare & Bioscience Institute



Scott A. LaGanga
Senior Vice President, State Government Affairs
Pharmaceutical Researchers and Manufacturers of America (PhRMA)

Our Commitment to *Beat* Coronavirus

We are **rapidly screening our vast global libraries of medicines** to identify potential treatments and have numerous clinical trials underway to test new and existing therapies

We are **dedicating our top scientists and using our investments in new technologies** to speed the development of safe and effective vaccines

We are **sharing the learnings from clinical trials in real time** with governments and other companies to advance the development of additional therapies

We are **expanding our unique manufacturing capabilities and sharing available capacity** to ramp up production once a successful medicine or vaccine is developed

We are **collaborating with government agencies, hospitals, doctors and others** to donate supplies and medicines to help those affected around the world

We are **working with governments and insurers** to ensure that when new treatments and vaccines are approved they will be available and affordable for patients

Developing Treatments and Vaccines to Fight COVID-19

There are **1772 clinical trials** under way
across the globe for vaccinations and treatments.



Data as of 3/5/2020

We are in a New Era of Medicine Where Breakthrough Science is Transforming Patient Care

53 New Medicines Were Approved by the FDA in 2020

**The
Washington
Post**


Cancer Death Rate

Cancer death rate posts biggest one-year drop ever

CBS

Game Changer

Newly approved drug being called 'game changer' for people who suffer from hemophilia




REUTERS

Coronavirus Vaccine

Reasons for hope: the drugs, tests and tactics that may conquer coronavirus

Insurers and PBMs Have a Lot of Leverage to Hold Down Medicine Costs

Negotiating power is increasingly concentrated among fewer pharmacy benefit managers (PBMs).



Insurers determine:

FORMULARY

if a medicine is covered

TIER PLACEMENT

patient cost sharing

ACCESSIBILITY


utilization management through prior authorization or fail first

PROVIDER INCENTIVES


preferred treatment guidelines and pathways

Patients Face Rising Out-of-pocket Costs for Medicines and Other Barriers to Care


Percent of plans with deductibles on prescription drugs



The use of four or more cost-sharing tiers is becoming more common on employer plans



Many of America's Biopharmaceutical Companies Are Expanding Their Assistance Programs To Help More People




950+

public and
private programs

The Medicine Assistance Tool (MAT) is a web platform designed to help patients, caregivers and health care providers learn more about some of the resources available to assist in affording their medicines.

www.MAT.org

Policies That Help *Patients Pay Less*



A decorative graphic on the left side of the slide. It features a cluster of white hexagons of varying sizes, some of which are interconnected by thin white lines. Within these hexagons are three distinct icons: a blue molecular structure, a teal Erlenmeyer flask with bubbles, and a red DNA double helix. Several white circles are also scattered around the hexagonal cluster. The background of the slide is a dark blue gradient with a subtle pattern of white hexagons and lines.

Questions?